Barros Andrea Barbieri, Rodrigues Alex Miranda, Batista Mariane Pereira, Munhoz Junior Sidney, Hueb Marcia, Fontes Cor Jesus
Hospital Universitário Júlio Müller, Universidade Federal de Mato Grosso, Cuiabá, MT, Brasil.
Mem Inst Oswaldo Cruz. 2014 Jul;109(4):499-501. doi: 10.1590/0074-0276130563. Epub 2014 Jul 3.
Antimony compounds are the cornerstone treatments for tegumentary leishmaniasis. The reactivation of herpes virus is a side effect described in few reports. We conducted an observational study to describe the incidence of herpes zoster reactivation during treatment with antimony compounds. The global incidence of herpes zoster is approximately 2.5 cases per 1,000 persons per month (or 30 cases per 1,000 persons per year). The estimated incidence of herpes zoster in patients undergoing antimony therapy is higher than previously reported.
锑化合物是皮肤利什曼病的基础治疗药物。疱疹病毒再激活是少数报告中描述的一种副作用。我们进行了一项观察性研究,以描述锑化合物治疗期间带状疱疹再激活的发生率。带状疱疹的全球发病率约为每月每1000人中有2.5例(或每年每1000人中有30例)。接受锑治疗的患者中带状疱疹的估计发病率高于先前报告的水平。